Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Endocrinol Metab. 2013 Feb;98(2):636-42. doi: 10.1210/jc.2012-3401. Epub 2013 Jan 4.

Papillary thyroid cancer: time course of recurrences during postsurgery surveillance.

Author information

1
Dipartimento di Medicina Interna e Specialità Medica, Università di Roma Sapienza, V.le del Policlinico, 155, 00161 Rome, Italy.

Abstract

CONTEXT:

The current use of life-long follow-up in patients with papillary thyroid cancer (PTC) is based largely on the study of individuals diagnosed and treated in the latter half of the 20th century when recurrence rates were approximately 20% and relapses detected up to 20-30 years after surgery. Since then, however, diagnosis, treatment, and postoperative monitoring of PTC patients have evolved significantly.

OBJECTIVES:

The objective of the study was to identify times to PTC recurrence and rates by which these relapses occurred in a more recent patient cohort.

PATIENTS AND DESIGN:

We retrospectively analyzed follow-up data for 1020 PTC patients consecutively diagnosed in 1990-2008 in 8 Italian hospital centers for thyroid disease. Patients underwent thyroidectomy, with or without radioiodine ablation of residual thyroid tissue and were followed up with periodic serum thyroglobulin assays and neck sonography.

RESULTS:

At the initial posttreatment (≤ 12 months) examination, 948 patients had no structural/functional evidence of disease. During follow-up (5.1-20.4 years; median 10.4 years), recurrence (cervical lymph nodes, thyroid bed) was diagnosed in 13 (1.4%) of these patients. All relapses occurred 8 or fewer years after treatment (10 within the first 5 years, 6 within the first 3 years). Recurrence was unrelated to the use/omission of postoperative radioiodine ablation.

CONCLUSION:

In PTC patients whose initial treatment produces disease remission (no structural evidence of disease), recurrent disease is rare, and it usually occurs during the early postoperative period. The picture of recurrence timing during the follow-up provides a foundation for the design of more cost-effective surveillance protocols for PTC patients.

PMID:
23293334
DOI:
10.1210/jc.2012-3401
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center